Dr. Jonathan Phillips has over 16 years nonclinical development experience and is currently Vice President of Pharmacology & Toxicology at Intellia Therapeutics in Cambridge, MA. Prior to Intellia, Dr. Phillips was a Fellow in Preclinical Safety Assessment at Vertex Pharmaceuticals where he co-authored CTA and IND applications for CTX001 (exa-cel) in collaboration with CRISPR Therapeutics. He is a past co-chairperson for the Predictive Safety Testing Consortium’s Nephrotoxicity Working Group (PSTC-NWG). Dr. Phillips holds a Ph.D. in Cell Biology from the University of Massachusetts Graduate School of Biomedical Sciences. He was awarded three rounds of graduate and postdoctoral funding from NASA including a GSRP grant, Bioastronautics and Fundamental Space Biology fellowship and NASA Postdoctoral Program fellowship at NASA Ames Research Center. Dr. Phillips has dozens of peer reviewed publications, book chapters and invited presentations in the field of biopharmaceutical development and safety.